857 related articles for article (PubMed ID: 27335373)
21. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
Ma J; Zhang B; Liu S; Xie S; Yang Y; Ma J; Deng Y; Wang W; Xu L; Li R; Zhang L; Yu C; Shi W
PLoS One; 2013; 8(5):e64912. PubMed ID: 23741418
[TBL] [Abstract][Full Text] [Related]
22. Proteome Analysis of Isolated Podocytes Reveals Stress Responses in Glomerular Sclerosis.
Koehler S; Kuczkowski A; Kuehne L; Jüngst C; Hoehne M; Grahammer F; Eddy S; Kretzler M; Beck BB; Höhfeld J; Schermer B; Benzing T; Brinkkoetter PT; Rinschen MM
J Am Soc Nephrol; 2020 Mar; 31(3):544-559. PubMed ID: 32047005
[TBL] [Abstract][Full Text] [Related]
23. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
[TBL] [Abstract][Full Text] [Related]
24. Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis.
Suzuki T; Matsusaka T; Nakayama M; Asano T; Watanabe T; Ichikawa I; Nagata M
Am J Pathol; 2009 May; 174(5):1675-82. PubMed ID: 19359523
[TBL] [Abstract][Full Text] [Related]
25. Role of C/EBP-α in Adriamycin-induced podocyte injury.
Zhong F; Wang W; Lee K; He JC; Chen N
Sci Rep; 2016 Sep; 6():33520. PubMed ID: 27644413
[TBL] [Abstract][Full Text] [Related]
26. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
27. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease.
Sonneveld R; Ferrè S; Hoenderop JG; Dijkman HB; Berden JH; Bindels RJ; Wetzels JF; van der Vlag J; Nijenhuis T
Am J Pathol; 2013 Apr; 182(4):1196-204. PubMed ID: 23385000
[TBL] [Abstract][Full Text] [Related]
29. c-Src is in the effector pathway linking uPAR and podocyte injury.
Kopp JB; Heymann J
J Clin Invest; 2019 Apr; 129(5):1827-1829. PubMed ID: 30939121
[TBL] [Abstract][Full Text] [Related]
30. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
[TBL] [Abstract][Full Text] [Related]
31. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis.
Guo J; Ananthakrishnan R; Qu W; Lu Y; Reiniger N; Zeng S; Ma W; Rosario R; Yan SF; Ramasamy R; D'Agati V; Schmidt AM
J Am Soc Nephrol; 2008 May; 19(5):961-72. PubMed ID: 18256352
[TBL] [Abstract][Full Text] [Related]
32. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy.
Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Takeuchi S; Tomioka M; Shigehara T; Maeshima A; Kaneko Y; Hiromura K; Kopp JB; Nojima Y
Nephrol Dial Transplant; 2009 Aug; 24(8):2378-83. PubMed ID: 19188342
[TBL] [Abstract][Full Text] [Related]
33. Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.
Chen CA; Hwang JC; Guh JY; Chang JM; Lai YH; Chen HC
J Lab Clin Med; 2006 Feb; 147(2):74-82. PubMed ID: 16459165
[TBL] [Abstract][Full Text] [Related]
34. A previously unrecognized role of C3a in proteinuric progressive nephropathy.
Morigi M; Locatelli M; Rota C; Buelli S; Corna D; Rizzo P; Abbate M; Conti D; Perico L; Longaretti L; Benigni A; Zoja C; Remuzzi G
Sci Rep; 2016 Jun; 6():28445. PubMed ID: 27345360
[TBL] [Abstract][Full Text] [Related]
35. Focal segmental glomerulosclerosis; why does it occur segmentally?
Nagata M; Kobayashi N; Hara S
Pflugers Arch; 2017 Aug; 469(7-8):983-988. PubMed ID: 28664408
[TBL] [Abstract][Full Text] [Related]
36. Podocyte-Specific Sialylation-Deficient Mice Serve as a Model for Human FSGS.
Niculovic KM; Blume L; Wedekind H; Kats E; Albers I; Groos S; Abeln M; Schmitz J; Beuke E; Bräsen JH; Melk A; Schiffer M; Weinhold B; Münster-Kühnel AK
J Am Soc Nephrol; 2019 Jun; 30(6):1021-1035. PubMed ID: 31040189
[TBL] [Abstract][Full Text] [Related]
37. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
38. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
Ilatovskaya DV; Staruschenko A
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F393-7. PubMed ID: 26084930
[TBL] [Abstract][Full Text] [Related]
39. The pathogenesis of focal segmental glomerulosclerosis.
Jefferson JA; Shankland SJ
Adv Chronic Kidney Dis; 2014 Sep; 21(5):408-16. PubMed ID: 25168829
[TBL] [Abstract][Full Text] [Related]
40. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders.
Lasagni L; Ballerini L; Angelotti ML; Parente E; Sagrinati C; Mazzinghi B; Peired A; Ronconi E; Becherucci F; Bani D; Gacci M; Carini M; Lazzeri E; Romagnani P
Stem Cells; 2010 Sep; 28(9):1674-85. PubMed ID: 20680961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
